Sana Hosseini

Nov 5, 2024 | drugdiscoveryonline.com | Martin J. Dahl |Sana Hosseini |Kim Shepard |John Chen

Drawing from experiences with ongoing work at AnaptysBio, Inc., senior VP of research Martin Dahl, Ph.D., shares three considerations when developing immune cell modulators to treat and modify inflammatory disease. Boost LNP Drug Potency With Optimized Delivery FormulationsLipid nanoparticles (LNPs) function as a drug delivery system for nucleic acids.